U.S. Pharmaceutical Sales - Q4 2013
The following is a list of the top 100 prescribed medicines by U.S. National Sales in Q4 2013. Figures include sales through both retail and hospital channels, listed by drug name and sales value in U.S. dollars. See also: Top 100 drugs for 2013
Last updated: February 2014 (updated quarterly).
Top 100 Drugs for Q4 2013 by Sales
- Sales Statistics Q4 2013
- Units*
Rank |
Drug |
Sales ($000) |
|
|
1 |
Abilify Otsuka Pharmaceutical Co., Ltd |
1,602,329 |
2.23% |
Stats |
2 |
Nexium AstraZeneca |
1,536,435 |
0.74% |
Stats |
3 |
Humira AbbVie Inc. |
1,461,861 |
3.86% |
Stats |
4 ( 1) |
Crestor AstraZeneca |
1,333,502 |
4.53% |
Stats |
5 ( 1) |
Advair Diskus GlaxoSmithKline |
1,247,330 |
2.65% |
Stats |
6 ( 1) |
Enbrel Amgen Inc. |
1,189,844 |
1.46% |
Stats |
7 ( 3) |
Cymbalta
|
1,064,186 |
-23.06% |
Stats |
8 |
Remicade Janssen Pharmaceuticals, Inc. |
994,020 |
-2.71% |
Stats |
9 |
Neulasta Amgen Inc. |
854,508 |
-4.90% |
Stats |
10 |
Copaxone Teva Pharmaceuticals USA, Inc. |
851,351 |
-4.69% |
Stats |
11 ( 1) |
Lantus Solostar Sanofi |
839,691 |
9.39% |
Stats |
12 ( 1) |
Rituxan Genentech, Inc. |
798,989 |
1.25% |
Stats |
13 |
Spiriva Boehringer Ingelheim Pharmaceuticals, Inc. |
746,766 |
-0.16% |
Stats |
14 ( 1) |
Januvia Merck |
700,941 |
3.63% |
Stats |
15 ( 1) |
Atripla Gilead Sciences, Inc. |
679,418 |
0.36% |
Stats |
16 ( 1) |
Lantus Sanofi |
675,461 |
5.84% |
Stats |
17 ( 1) |
Avastin Genentech, Inc. |
650,208 |
-1.25% |
Stats |
18 |
Lyrica Pfizer Inc. |
624,774 |
2.82% |
Stats |
19 |
OxyContin Purdue Pharma LP |
585,482 |
-2.91% |
Stats |
20 |
Epogen Amgen Inc. |
580,570 |
1.54% |
Stats |
21 |
Celebrex Pfizer Inc. |
580,332 |
5.23% |
Stats |
22 |
Truvada Gilead Sciences, Inc. |
542,846 |
0.03% |
Stats |
23 |
Diovan Novartis Pharmaceuticals Corporation |
533,924 |
2.80% |
Stats |
24 ( 1) |
Gleevec Novartis Pharmaceuticals Corporation |
498,149 |
7.22% |
Stats |
25 ( 1) |
Herceptin Genentech, Inc. |
473,632 |
1.53% |
Stats |
26 |
Lucentis Genentech, Inc. |
460,621 |
-0.84% |
Stats |
27 ( 2) |
Vyvanse Takeda Pharmaceutical Company Limited |
447,188 |
9.39% |
Stats |
28 |
Zetia Merck |
444,731 |
4.04% |
Stats |
29 ( 2) |
Namenda Allergan plc |
434,766 |
-6.00% |
Stats |
30 |
Levemir Novo Nordisk |
424,186 |
9.34% |
Stats |
31 ( 1) |
Symbicort AstraZeneca |
407,646 |
9.63% |
Stats |
32 ( 5) |
Tecfidera Biogen |
391,404 |
20.28% |
Stats |
33 ( ) |
ONE TOUCH ULTRA
|
370,899 |
n/a |
Stats |
34 ( 1) |
NovoLog FlexPen Novo Nordisk |
364,870 |
7.84% |
Stats |
35 ( 1) |
AndroGel AbbVie Inc. |
351,737 |
5.47% |
Stats |
36 ( 1) |
Novolog Novo Nordisk |
344,235 |
3.86% |
Stats |
37 ( 1) |
enoxaparin Generic |
341,184 |
6.55% |
Stats |
38 ( 1) |
methylphenidate Generic |
327,346 |
2.26% |
Stats |
39 ( 3) |
Suboxone
|
321,892 |
-2.11% |
Stats |
40 ( 10) |
Xarelto
|
321,462 |
18.72% |
Stats |
41 ( 7) |
ProAir HFA Teva Pharmaceuticals USA, Inc. |
306,461 |
10.87% |
Stats |
42 ( 1) |
Humalog Eli Lilly and Company |
304,866 |
6.15% |
Stats |
43 ( 3) |
Alimta Eli Lilly and Company |
302,728 |
6.00% |
Stats |
44 ( 5) |
Victoza Novo Nordisk |
301,414 |
9.59% |
Stats |
45 ( 3) |
Viagra Pfizer Inc. |
300,463 |
3.26% |
Stats |
46 ( 1) |
Seroquel XR AstraZeneca |
291,494 |
2.22% |
Stats |
47 ( ) |
Synagis MedImmune, Inc. |
289,704 |
n/a |
Stats |
48 ( 3) |
Avonex Biogen |
281,554 |
-1.43% |
Stats |
49 ( 19) |
Renvela Sanofi |
280,917 |
21.44% |
Stats |
50 ( 9) |
Rebif EMD Serono, Inc. |
280,548 |
-6.27% |
Stats |
51 ( 1) |
Cialis Eli Lilly and Company |
280,518 |
4.58% |
Stats |
52 ( 1) |
Gilenya Novartis Pharmaceuticals Corporation |
272,701 |
4.05% |
Stats |
53 ( 1) |
Nasonex Merck |
272,345 |
5.67% |
Stats |
54 ( 8) |
Stelara Janssen Pharmaceuticals, Inc. |
270,598 |
12.47% |
Stats |
55 ( 2) |
Restasis Allergan plc |
268,463 |
6.30% |
Stats |
56 ( 22) |
budesonide Generic |
268,201 |
26.81% |
Stats |
57 ( 2) |
acetaminophen/hydrocodone Generic |
264,814 |
6.67% |
Stats |
58 ( 11) |
Flovent HFA GlaxoSmithKline |
263,072 |
13.97% |
Stats |
59 ( 1) |
Lovaza GlaxoSmithKline |
258,177 |
2.90% |
Stats |
60 ( 1) |
Prezista Janssen Pharmaceuticals, Inc. |
251,372 |
3.54% |
Stats |
61 ( 1) |
Isentress Merck |
248,924 |
0.72% |
Stats |
62 ( 4) |
Janumet Merck |
247,150 |
4.65% |
Stats |
63 ( 12) |
Procrit Janssen Pharmaceuticals, Inc. |
241,535 |
-10.09% |
Stats |
64 ( 9) |
doxycycline Generic |
241,381 |
-5.65% |
Stats |
65 ( 1) |
Orencia Bristol-Myers Squibb Company |
241,149 |
1.65% |
Stats |
66 ( 1) |
amphetamine/dextroamphetamine Generic |
240,482 |
2.78% |
Stats |
67 ( 4) |
VESIcare Astellas Pharma US, Inc. |
240,435 |
5.37% |
Stats |
68 ( 4) |
Dexilant Takeda Pharmaceutical Company Limited |
238,897 |
7.57% |
Stats |
69 ( 7) |
Humalog KwikPen Eli Lilly and Company |
238,418 |
11.02% |
Stats |
70 ( 5) |
Neupogen Amgen Inc. |
229,912 |
-2.70% |
Stats |
71 ( ) |
lidocaine Generic |
225,903 |
n/a |
Stats |
72 ( 5) |
Lunesta Sunovion Pharmaceuticals Inc. |
225,101 |
5.24% |
Stats |
73 ( 3) |
fenofibrate Generic |
223,300 |
-2.22% |
Stats |
74 ( 12) |
Zytiga Janssen Pharmaceuticals, Inc. |
222,026 |
11.86% |
Stats |
75 ( 2) |
Reyataz Bristol-Myers Squibb Company |
217,793 |
-1.38% |
Stats |
76 ( 15) |
Sensipar Amgen Inc. |
216,657 |
13.71% |
Stats |
77 ( 2) |
metoprolol Generic |
215,111 |
2.99% |
Stats |
78 ( 11) |
Invega Sustenna Janssen Pharmaceuticals, Inc. |
214,251 |
10.03% |
Stats |
79 ( 4) |
Synthroid AbbVie Inc. |
213,424 |
-2.50% |
Stats |
80 ( 12) |
Avonex Pen Biogen |
211,917 |
13.59% |
Stats |
81 ( 7) |
Prevnar 13 Pfizer Inc. |
209,367 |
6.41% |
Stats |
82 ( 1) |
Xolair
|
207,891 |
1.91% |
Stats |
83 ( 2) |
Combivent Respimat Boehringer Ingelheim Pharmaceuticals, Inc. |
207,542 |
4.23% |
Stats |
84 ( ) |
levothyroxine Generic |
204,755 |
n/a |
Stats |
85 ( 2) |
Benicar Daiichi Sankyo |
203,336 |
3.22% |
Stats |
86 ( ) |
Stribild Gilead Sciences, Inc. |
202,642 |
n/a |
Stats |
87 ( 12) |
Zostavax Merck |
202,240 |
15.17% |
Stats |
88 ( 4) |
Pradaxa Boehringer Ingelheim Pharmaceuticals, Inc. |
200,697 |
-0.53% |
Stats |
89 ( 9) |
Vytorin Merck |
199,625 |
-3.02% |
Stats |
90 ( ) |
Tamiflu
|
197,718 |
n/a |
Stats |
91 ( 1) |
Xgeva Amgen Inc. |
197,711 |
3.24% |
Stats |
92 ( 11) |
Evista
|
196,929 |
-4.31% |
Stats |
93 ( 2) |
Xeloda Genentech, Inc. |
194,044 |
6.52% |
Stats |
94 ( 12) |
Aranesp Amgen Inc. |
185,225 |
-9.22% |
Stats |
95 ( ) |
Ventolin HFA GlaxoSmithKline |
183,060 |
n/a |
Stats |
96 ( ) |
divalproex sodium Generic |
181,554 |
n/a |
Stats |
97 ( 1) |
Afinitor Novartis Pharmaceuticals Corporation |
180,719 |
0.03% |
Stats |
98 ( 5) |
Betaseron Bayer HealthCare Pharmaceuticals Inc. |
179,216 |
-3.72% |
Stats |
99 ( 1) |
Adderall XR Takeda Pharmaceutical Company Limited |
177,505 |
3.31% |
Stats |
100 ( ) |
Complera Gilead Sciences, Inc. |
174,933 |
n/a |
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.